Relapse Remitting Multiple Sclerosis
Neurology
Prevalence
26.5 / 100K
Incidence
0.8 / 100K/yr
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 4(1)
| Drug | Company |
|---|---|
| ofatunumab | Novartis AG (NVS) |
Frequently asked questions
How many drugs are in development for Relapse Remitting Multiple Sclerosis?
BioSniper tracks 1 drug in development for Relapse Remitting Multiple Sclerosis across 1 company.
How many clinical trials target Relapse Remitting Multiple Sclerosis?
There are 1 clinical trial targeting Relapse Remitting Multiple Sclerosis tracked by BioSniper.
What is the prevalence of Relapse Remitting Multiple Sclerosis?
The estimated prevalence of Relapse Remitting Multiple Sclerosis is approximately 26.5 per 100,000 population.
Deep-dive into Relapse Remitting Multiple Sclerosis
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis